Beyond the triad: Inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita - 14/03/18
Doi : 10.1016/j.jaad.2017.10.017
Suzanne C. Ward, BE a, Sharon A. Savage, MD b, Neelam Giri, MD b, Blanche P. Alter, MD, MPH b, Philip S. Rosenberg, PhD c, Dominique C. Pichard, MD a, Edward W. Cowen, MD, MHSc a, ⁎ 
a Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
b Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
c Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
∗Correspondence to: Edward W. Cowen, MD, MHSc, Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Building 10 Rm, 12N240A, MSC 1908, 10 Center Dr, Bethesda, MD 20892-1908Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Institutes of HealthBuilding 10 Rm, 12N240A, MSC 1908, 10 Center DrBethesdaMD20892-1908
| Drs Pichard and Cowen are now affiliated with the National Institute of Arthritis and Musculoskeletal and Skin Diseases. |
|
| Supported through the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), and the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and generous contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation, American Association for Dental Research, Colgate-Palmolive Company, Genentech, and alumni of student research programs and other individual supporters via contributions to the Foundation for the NIH. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2017
Publié par Elsevier Masson SAS.
Vol 78 - N° 4
P. 804-806 - avril 2018 Retour au numéro
Article précédent
- Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study
- Arvin Ighani, Jorge R. Georgakopoulos, Neil H. Shear, Scott Walsh, Jensen Yeung
- Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center
- Keshavamurthy Vinay, Simone Cazzaniga, Kyle T. Amber, Laurence Feldmeyer, Luigi Naldi, Luca Borradori
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?